Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis
Top Cited Papers
- 1 December 2006
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 103 (3), 1070-1076
- https://doi.org/10.1016/j.ygyno.2006.06.025
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Discordance between beliefs and recommendations of gynecologic oncologists in ovarian cancer management*International Journal of Gynecologic Cancer, 2004
- The potential role of neoadjuvant chemotherapy in advanced ovarian cancerInternational Journal of Gynecologic Cancer, 2003
- Can Serum CA-125 Levels Predict the Optimal Primary Cytoreduction in Patients with Advanced Ovarian Carcinoma?Gynecologic Oncology, 2002
- The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Meta-analysis Comparing Cisplatin Total Dose Intensity and SurvivalGynecologic Oncology, 1995
- Extensive Primary Cytoreductive Surgery for Advanced Epithelial Ovarian CancerGynecologic Oncology, 1994
- Intervention debulking surgery in advanced epithelial ovarian cancerBJOG: An International Journal of Obstetrics and Gynaecology, 1994
- Improved prognosis of ovarian cancer in The Netherlands during the period 1975–1985: A registry-based studyGynecologic Oncology, 1991
- A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectivesEuropean Journal of Cancer and Clinical Oncology, 1989